Phospho-ERBB2 (Y1112) Antibody

Gene References and Functions

1. This abnormally sensitive electrochemical sensing performance, resulting from anionic porphyrin for DNA sequences specific to the HER2 gene, holds significant promise for tumor diagnosis and treatment. PMID: 30340409
2. Researchers demonstrated that mRNA and protein levels of COX2 and HER2 were upregulated in CRC compared to adjacent tissues. COX2 protein levels and nuclear COX2 expression correlated with a poor prognosis for CRC patients. COX2 expression was positively associated with HER2 expression. PMID: 29873317
3. In patients with HER2-positive advanced breast cancer who have received extensive prior treatment with anti-HER2 agents and cytotoxic chemotherapy, trastuzumab emtansine (T-DM1) exhibited good tolerability and provided a significant progression-free survival of 6 months. Overall survival has not yet been reached. PMID: 29326401
4. The expression of C-Met and HER2 protein in lung adenocarcinoma is highly correlated. Further research is warranted to investigate whether their combined targeting offers synergistic effects in the treatment of lung adenocarcinoma. PMID: 29400000
5. While ST6GalI overexpression led to increased HER2 sialylation, corresponding to decreased HER2 phosphorylation, high alpha2,6sialylation enhanced Akt and ERK phosphorylation levels compared to the vector cell line. Conversely, ST6GalI knockdown had the opposite effects. These findings suggest a functional role for ST6GalI in promoting tumor cell progression and trastuzumab resistance. PMID: 30226606
6. This study demonstrates that miR-495 exerts promotive effects on GC chemosensitivity by inactivating the mTOR signaling pathway through suppression of ERBB2. The study provides solid evidence supporting the potential use of miR-495 as a novel target in GC chemotherapy. PMID: 30147110
7. In early breast cancer, PIK3CA mutations appear to identify HER2+ patients who are less likely to achieve pCR. The clinical implications of PIK3CA mutations tend to vary between exon 9 and exon 20. This mechanism requires further exploration in future studies. PMID: 29575819
8. HER2 and HER3 expression was detected in 22.2% and 86.1% of samples, respectively. The frequency of EGFR mutation was 45.7% and was not significantly different between stage 0 and IA1 (40.0% and 48.0%, respectively), suggesting that EGFR mutation does not correlate with cancer progression from stage 0 to IA1. PMID: 29473311
9. Research has demonstrated that the heterogeneity of HER2 expression accelerates the development of metastases, leading to poorer survival rates in mice with heterogeneous HER2 expression (HER2-60). PMID: 30042341
10. Her-2/neu amplification increases with increasing grade of breast cancer. A high proportion of Her-2/neu gene amplified cases indicates aggressive disease in that area and necessitates FISH testing on a large scale, which is the gold standard for equivocal cases on immunohistochemistry. PMID: 30060783
11. Data indicate that the major mechanism involves the ability of p140Cap to interfere with ERBB2-dependent activation of Rac GTPase-controlled circuitries. PMID: 28300085
12. A study showed that the expression levels of Gli1 and HER2 were significantly higher in gastric cancer and positively related. HER2 may regulate Gli1 through the Akt-mTOR-p70S6K pathway. PMID: 29321573
13. The combination of immunohistochemical expression of BRCA1, ER, PR, and HER-2/neu, along with clinicopathological details, may be helpful in identifying individuals more likely to carry BRCA1 mutations. This approach can aid in selecting candidates and family members for genetic screening for BRCA1 mutations. PMID: 29567881
14. In current settings, HER2/neu is not found to be a prognostic marker in head-and-neck cancers. PMID: 30004046
15. These results indicate a potential link between HE4 expression and HER2/neu amplification. PMID: 30004048
16. HER2 gene amplification in circulating tumor DNA predicts resistance to trastuzumab emtansine in HER2-positive breast neoplasms. PMID: 29700710
17. Statistical analysis performed in this study did not reveal a significant relationship between HER2 overexpression on tumor cells and microvessel density in the tumor stroma. PMID: 30334990
18. Data showed a high rate of discordance in matched pairs of primary tumors and metastases, suggesting that accurate evaluation of proto-oncogene protein HER-2 (HER2) status is crucial before making any therapeutic decisions. PMID: 30203148
19. HER2 gene amplification occurred during the early stages of gastric cancer and exhibited heterogeneity in several cases. HER2 gene amplification may play a role in tumor progression in early gastric cancer. PMID: 30120594
20. Activating HER2 mutations are present in approximately 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer. PMID: 30094493
21. The results suggest a potential link between tRNALeu overexpression and RSK1/MSK2 activation, particularly in breast cancer, along with ErbB2/ErbB3 signaling. PMID: 28816616
22. High HER2 expression is associated with metastasis in breast cancer. PMID: 29187405
23. This study confirms that biosimilar trastuzumab improves the overall response rate when combined with chemotherapy for HER2+ breast cancer. PMID: 30082554
24. Researchers identified a gender difference in the prognostic value of concomitant AIB1 and HER2 copy number gain (CNG) in glioma patients, which was previously overlooked. These findings suggest that genetic alterations, acting in synergy with essential aspects of sex determination, influence glioma biology and patient outcomes. PMID: 30153912
25. The survival rates observed in this study are comparable to documented global rates. Nodal disease burden emerged as the most important prognostic factor. Additionally, in EBCs, a lack of hormone receptor expression and in LABC, Her2neu overexpression appear to worsen the outcome. PMID: 30147088
26. Results indicate that DDX6 regulates HER2 and FGFR2 at the post-transcriptional step in gastric cancer. PMID: 29987267
27. HER2 overexpression is associated with Gastric Cancer. PMID: 29938472
28. The ERBB2 oncogene at 17q12 is susceptible to palindromic gene amplification in HER2-positive breast tumors. PMID: 28211519
29. Results show that mutations in ERBB2-exon17 were associated with poorer survival outcomes in patients with pancreatic neoplasm. [review] PMID: 30227250
30. High HER2 expression and gene amplification are associated with Upper Tract Urothelial Carcinomas. PMID: 28755093
31. High HER2 expression is associated with invasion and lymph node metastasis in gastric cancer. PMID: 29970682
32. The basal HER2 phenotype exhibited poor DFS but an equivalent pCR rate after concurrent neo-adjuvant chemotherapy with trastuzumab. A distinct treatment approach is needed for basal-HER2 type, even for cases that achieved adequate clinical response after neo-adjuvant chemotherapy. PMID: 29971625
33. In the largest series reported to date, patients with HER2-amplified m17 cancers treated with trastuzumab had outcomes comparable to patients from large phase III adjuvant trastuzumab trials who were HER2-positive, supporting the critical role of HER2-directed therapy in this patient population. PMID: 28986743
34. The interplay of dual MET/HER2 overexpression in the AKT and ERK pathways for esophageal cancer is described. Therefore, combination therapy could be a novel strategy for EAC with amplification of both MET and HER2. PMID: 29223420
35. This study provides evidence that the hostile environment developed in spheroids plays a key role in the acquisition of resistance to Trastuzumab. This is associated with an increase in the number of breast cancer stem cells, as well as modulation in HER2 expression. PMID: 28722778
36. A major finding of this study is that one in five (20%) patients with breast cancer BM had a receptor discrepancy between the primary tumor and the subsequent BM. Loss of hormone receptor (ER and/or PR) expression and gain of HER2 overexpression were the most commonly observed changes. PMID: 28975433
37. High HER2 expression is associated with Gastric Adenocarcinoma. PMID: 29802704
38. The absence of HER2 expression in circulating tumor cells is associated with non-metastatic esophageal cancer. PMID: 30275185
39. HER2 positivity was found in a minority of rectal cancer patients and was not significantly associated with clinicopathologic and molecular characteristics. PMID: 30056472
40. Researchers discovered a novel enhancer, the HER2 gene body enhancer (HGE), in the 3' gene body of HER2. The HGE activates promoters 1 and 2 in trans, thus leading to TFAP2C-mediated transcriptional induction of HER2 expression in breast cancer samples. PMID: 29035388
41. ctDNA gene mutation profiles differed among HR/HER2 subtypes of metastatic breast cancer (MBC) patients. By identifying mutations associated with treatment resistance, researchers hope to improve therapy selection for MBC patients who have received multiple lines of treatment. PMID: 29807833
42. It was concluded that miR494 inhibited the cancer-initiating cells phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2-positive gastric cancer. PMID: 29786108
43. HER2 overexpression was evident in nearly 25% of Malaysian patients with locally advanced or metastatic gastric cancer. The overexpression correlated significantly with male gender and diffuse-type tumors. PMID: 28124769
44. A statistically significant association was found between positive p95-HER2 expression and negative hormonal receptors expression (p=0.004), high Ki-67 expression (p<0.001), and the development of visceral metastasis. PMID: 29779938
45. This study provides evidence that the transcriptional repressor Blimp1 is a novel mediator of p130Cas/ErbB2-mediated invasiveness. High Blimp1 expression levels are detected in invasive p130Cas/ErbB2 cells and correlate with metastatic status in human breast cancer patients. PMID: 28442738
46. ERBB2 amplification is a driving force behind resistance to erlotinib in lung adenocarcinoma. PMID: 28870636
47. Results showed that combining the results of IHC and FISH according to the HER2 testing algorithm is a useful method for accurately evaluating HER2-positive EMPD. PMID: 29744813
48. Because the concordance rates of HER2 IHC score 2/3+ cases were lower than that of HER2 IHC score 0/1+ cases, further studies are needed to develop detailed analysis criteria for HER2 IHC score 2+ or 3+. PMID: 28478639
49. HER2 interacts with Beclin 1 in breast cancer cells and inhibits autophagy. Mice with increased basal autophagy due to a genetically engineered mutation in Becn1 are protected from human HER2-driven mammary tumorigenesis. HER2-mediated inhibition of Beclin 1 and autophagy likely contributes to HER2-mediated tumorigenesis. PMID: 29610308
50. These findings suggest that early-stage morphological alterations of HER2-positive BC cells during cancer progression can occur in a physical and signaling-independent manner. PMID: 27599456

Show More

Hide All

HGNC: 3430

OMIM: 137800

KEGG: hsa:2064

STRING: 9606.ENSP00000269571

UniGene: Hs.446352